- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04593680
Assessment of Drug-drug Interactions Between Masculinizing Hormone Therapy and Antiretroviral Agents Concomitantly for Pre-exposure Prophylaxis Among Transgender Men
Institute of HIV Research and Innovation (IHRI)
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Nittaya Phanuphak, MD, PhD
- Phone Number: 881 8253544
- Email: nittaya.p@ihri.org
Study Contact Backup
- Name: Rena Janamnuaysook, MBA
- Phone Number: +662 2530996
- Email: rena.j@ihri.org
Study Locations
-
-
Pathumwan
-
Bangkok, Pathumwan, Thailand, 10330
- Recruiting
- Institute of HIV Research and Innovation (IHRI)
-
Contact:
- Nittaya Phanuphak, MD, PhD
- Phone Number: +662253 0996
- Email: nittaya.p@ihri.org
-
Contact:
- Rena Janamnuaysook, MBA
- Phone Number: +662253 0996
- Email: rena.j@ihri.org
-
Principal Investigator:
- Nittaya Phanuphak, MD,PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Thai nationality
- Age 18-40 years old
- Female-to-Male transgender individual
- HIV-negative
- Body mass index 18.5-24.9 kg/m2
- Negative urine pregnancy test
- Calculated creatinine clearance (CrCl) ≥60 mL/min, as estimated by the Cockcroft-Gault equation
- Alanine aminotransferase (ALT) ≤2.5 x ULN
- Signed the informed consent form
Exclusion Criteria:
- Known history of allergy to hormonal component to be used in the study
- Use of pre-exposure prophylaxis or post-exposure prophylaxis in the past 30 days
- Use of injectable MHT in the past 3 months
- Evidence of current hepatitis B virus infection (HBV) - i.e. hepatitis B surface antigen [HBsAg] positive
- Evidence of current hepatitis C virus infection (HCV) - i.e. HCV antibody positive
- History of myocardial infarction or coronary artery disease
Current use of any of the following:
- Anticonvulsants: carbamazepine, oxcarbazepine, phenytoin, or phenobarbital
- Herbs: gingko biloba, St John's wort or milk thistle
- Anti-infective agents: protease inhibitors, rifampicin or rifabutin
- History of gastrointestinal tract surgery that alter gastrointestinal tract and/or drug absorption
- Alcohol or drug use that, in the opinion of the investigator, would interfere with completion of study procedures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 20 HIV-negative TGM will take daily TDF/FTC-based PrEP
MHT will be initiated on week 0 and will be last administered on week 12. PrEP will be initiated on week 6 and continued without interruption. MHT: Intramuscular testosterone enanthate 200 mg bi-weekly, which is the treatment of choice for MHT in the Pribta Clinic, will be provided to all participants. PrEP: Fixed-dose combination of emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (F/TDF) and emtricitabine 200 mg/tenofovir alafenamide 25 mg (F/TAF) will be provided for arm 1 and 2, respectively. Pharmacokinetic measurement of study drug Two full pharmacokinetic (PK) measurements will be performed. Samples collected will include: plasma for testosterone, emtricitabine (FTC) and tenofovir (TFV), with an additional tenofovir alafenamide (TAF). |
The first full PK measurement of MHT will be performed starting at week 4 and end at week 6 to assess the steady-state plasma PK of testosterone in the absence of PrEP.
The second PK measurement of MHT will be performed starting at week 12 and end at week 14 to assess plasma PK of testosterone in the presence of both MHT and PrEP.
The first full PK measurement of PrEP will be performed at week 12 to assess the steady-state plasma PK of FTC, TFV, and TAF; and intracellular PBMC FTC-TP and TFV-DP in the presence of both MHT and PrEP.
The second measurement of PrEP will be performed at week 16 to assess plasma PK of FTC, TFV, and TAF; and intracellular PBMC FTC-TP and TFV-DP in the absence of MHT.
|
EXPERIMENTAL: 20 HIV-negative TGM will take daily F/TAF-based PrEP
MHT will be initiated on week 0 and will be last administered on week 12. PrEP will be initiated on week 6 and continued without interruption. MHT: Intramuscular testosterone enanthate 200 mg bi-weekly, which is the treatment of choice for MHT in the Pribta Clinic, will be provided to all participants. PrEP: Fixed-dose combination of emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (F/TDF) and emtricitabine 200 mg/tenofovir alafenamide 25 mg (F/TAF) will be provided for arm 1 and 2, respectively. Pharmacokinetic measurement of study drug Two full pharmacokinetic (PK) measurements will be performed. Samples collected will include: arm 2, measurement; and peripheral blood mononuclear cells (PBMC) for emtricitabine-triphosphate (FTC-TP) and tenofovir-diphosphate (TFV-DP) intracellular quantification. |
The first full PK measurement of MHT will be performed starting at week 4 and end at week 6 to assess the steady-state plasma PK of testosterone in the absence of PrEP.
The second PK measurement of MHT will be performed starting at week 12 and end at week 14 to assess plasma PK of testosterone in the presence of both MHT and PrEP.
The first full PK measurement of PrEP will be performed at week 12 to assess the steady-state plasma PK of FTC, TFV, and TAF; and intracellular PBMC FTC-TP and TFV-DP in the presence of both MHT and PrEP.
The second measurement of PrEP will be performed at week 16 to assess plasma PK of FTC, TFV, and TAF; and intracellular PBMC FTC-TP and TFV-DP in the absence of MHT.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in plasma TFV level
Time Frame: 2 years
|
|
2 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- iMACT
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug Interaction
-
Hutchison Medipharma LimitedCompletedFood-drug Interaction | Drug InteractionUnited States
-
University of Southern CaliforniaRecruitingDrug Drug InteractionUnited States
-
Daewoong Pharmaceutical Co. LTD.Active, not recruitingDrug Drug InteractionKorea, Republic of
-
Daewoong Pharmaceutical Co. LTD.Enrolling by invitationDrug-drug InteractionKorea, Republic of
-
Daewoong Pharmaceutical Co. LTD.CompletedDrug Drug InteractionKorea, Republic of
-
ItalfarmacoCompletedDrug-Drug InteractionPortugal
-
Aurinia Pharmaceuticals Inc.CompletedDrug-drug InteractionUnited States
-
Blade TherapeuticsCompletedDrug Drug InteractionUnited States
-
Daewoong Pharmaceutical Co. LTD.CompletedDrug-drug InteractionAustralia
-
Nanjing Yoko Biomedical Co., Ltd.CompletedDrug-drug InteractionChina
Clinical Trials on Emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (F/TDF) and emtricitabine 200 mg/tenofovir alafenamide 25 mg (F/TAF)
-
University of California, San DiegoActive, not recruitingHiv | Hormone TherapyUnited States
-
Merck Sharp & Dohme LLCCompleted
-
Hospital Italiano de Buenos AiresSociedad Argentina de Infectología (SADI) (Argentine Society of Infectious...UnknownCOVID-19 | Healthcare Workers | SARS-CoV 2Argentina
-
State University of New York at BuffaloGilead SciencesActive, not recruiting
-
HQ TorontoGilead SciencesActive, not recruiting
-
Fundacion SEIMC-GESIDAActive, not recruiting
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...Completed
-
Chinese University of Hong KongCompleted
-
Gilead SciencesActive, not recruitingPre-Exposure Prophylaxis of HIV-1 InfectionUnited States, Austria, Denmark, United Kingdom, Netherlands, Italy, Germany, Canada, Ireland, France, Spain
-
University of Colorado, DenverCompletedHealthy Volunteers | Pharmacokinetics